FOREWORD The (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headqu
|
|
- Harriet Atkins
- 6 years ago
- Views:
Transcription
1 NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF ANTIMONY TRIOXIDE (CAS NO ) IN WISTAR HAN [Crl:WI (Han)] RATS AND B6C3F1/N MICE (INHALATION STUDIES) Scheduled Peer Review Date: February 16, 2016 NOTICE This DRAFT Technical Report is distributed solely for the purpose of predissemination peer review under the applicable information quality guidelines. It has not been formally disseminated by the NTP. It does not represent and should not be construed to represent NTP determination or policy. NTP TR 590 National Institutes of Health Public Health Service U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 47
2 FOREWORD The (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public. The Technical Report series began in 1976 with carcinogenesis studies conducted by the National Cancer Institute. In 1981, this bioassay program was transferred to the NTP. The studies described in the Technical Report series are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected substances in laboratory animals (usually two species, rats and mice). Substances selected for NTP toxicity and carcinogenicity studies are chosen primarily on the basis of human exposure, level of production, and chemical structure. The interpretive conclusions presented in NTP Technical Reports are based only on the results of these NTP studies. Extrapolation of these results to other species, including characterization of hazards and risks to humans, requires analyses beyond the intent of these reports. Selection per se is not an indicator of a substance s carcinogenic potential. The NTP conducts its studies in compliance with its laboratory health and safety guidelines and FDA Good Laboratory Practice Regulations and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use are in accordance with the Public Health Service Policy on Humane Care and Use of Animals. Studies are subjected to retrospective quality assurance audits before being presented for public review. NTP Technical Reports are indexed in the NIH/NLM PubMed database and are available free of charge electronically on the NTP website ( 48
3 NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF ANTIMONY TRIOXIDE (CAS NO ) IN WISTAR HAN [Crl:WI (Han)] RATS AND B6C3F1/N MICE (INHALATION STUDIES) Scheduled Peer Review Date: February 16, 2016 NOTICE This DRAFT Technical Report is distributed solely for the purpose of predissemination peer review under the applicable information quality guidelines. It has not been formally disseminated by the NTP. It does not represent and should not be construed to represent NTP determination or policy. NTP TR 590 National Institutes of Health Public Health Service U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 49
4 2 CONTRIBUTORS Evaluated and interpreted results and reported findings M.D. Stout, Ph.D., Co-Study Scientist B.C. Sayers, Ph.D., Co-Study Scientist G.P. Flake, M.D., Study Pathologist C.R. Blystone, Ph.D. P.M. Foster, Ph.D. R.A. Herbert, D.V.M., Ph.D. M.J. Hooth, Ph.D. A.P. King-Herbert, D.V.M. G.E. Kissling, Ph.D. D.E. Malarkey, D.V.M., Ph.D. A.R. Pandiri, B.V.Sc. & A.H., Ph.D. S.L. Smith-Roe, Ph.D. G.S. Travlos, D.V.M. M.K. Vallant, B.S., M.T. S. Waidyanatha, Ph.D. N.J. Walker, Ph.D. K.L. Witt, M.S. Battelle Toxicology Northwest Conducted studies and evaluated pathology findings J.A. Dill, Ph.D., Principal Investigator S.L. Grumbein, D.V.M., Ph.D. B.K. Hayden K.M. Patton, D.V.M., Ph.D. L.M. Staska, D.V.M., Ph.D. Experimental Pathology Laboratories, Inc. Provided pathology review M.H. Hamlin, II, D.V.M., Principal Investigator R.A. Miller, D.V.M., Ph.D. A.R. Pandiri, B.V.Sc. & A.H., Ph.D. Dynamac Corporation Prepared quality assessment audits S. Brecher, Ph.D., Principal Investigator S. Iyer, B.S. V.S. Tharakan, D.V.M. NTP Pathology Working Group Evaluated slides and contributed to pathology report on 2-year rats (October 17, 2013, and November 14, 2013) J.S. Hoane, D.V.M., Coordinator Pathology Associates International, A Charles River Company M.F. Cesta, D.V.M., Ph.D. S.A. Elmore, D.V.M., M.S. G.P. Flake, M.D. R.A. Herbert, D.V.M., Ph.D. M.P. Jokinen, D.V.M. ILS, Inc. R.A. Miller, D.V.M., Ph.D. Experimental Pathology Laboratories, Inc. A.R. Pandiri, B.V.Sc. & A.H., Ph.D. Experimental Pathology Laboratories, Inc. L.M. Staska, D.V.M., Ph.D. ILS, Inc. Evaluated slides and contributed to pathology report on 2-year mice (December 10, 2013) K.A. Szabo, D.V.M., M.S., Coordinator Pathology Associates International, A Charles River Company M.F. Cesta, D.V.M., Ph.D. S.A. Elmore, D.V.M., M.S. G.P. Flake, M.D. M.P. Jokinen, D.V.M. ILS, Inc. R.A. Miller, D.V.M., Ph.D. Experimental Pathology Laboratories, Inc. A.R. Pandiri, B.V.Sc. & A.H., Ph.D. Experimental Pathology Laboratories, Inc. E.M. Quist, D.V.M., M.S. D.B. Rao, B.V.Sc., Ph.D. ILS, Inc. 50
5 Antimony Trioxide, NTP TR Social & Scientific Systems, Inc. Provided statistical analyses M.V. Smith, Ph.D., Principal Investigator L.J. Betz, M.S. S.F. Harris, B.S. Biotechnical Services, Inc. Prepared Technical Report S.R. Gunnels, M.A., Principal Investigator P.A. Gideon, B.A. B.F. Hall, M.S. L.M. Harper, B.S. D.C. Serbus, Ph.D. 51
6 4 CONTENTS ABSTRACT... 7 EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY...19 PEER REVIEW PANEL...20 SUMMARY OF PEER REVIEW PANEL COMMENTS...21 INTRODUCTION...23 MATERIALS AND METHODS...35 RESULTS...53 DISCUSSION AND CONCLUSIONS REFERENCES APPENDIX A APPENDIX B APPENDIX C APPENDIX D APPENDIX E Summary of Lesions in Male Rats in the 2-Year Inhalation Study of Antimony Trioxide...A-1 Summary of Lesions in Female Rats in the 2-Year Inhalation Study of Antimony Trioxide...B-1 Summary of Lesions in Male Mice in the 2-Year Inhalation Study of Antimony Trioxide...C-1 Summary of Lesions in Female Mice in the 2-Year Inhalation Study of Antimony Trioxide...D-1 Genetic Toxicology...E-1 APPENDIX F Organ Weights and Organ-Weight-to-Body Weight Ratios... F-1 APPENDIX G Tissue Burden Results... G-1 APPENDIX H Chemical Characterization and Generation of Chamber Concentrations... H-1 APPENDIX I Ingredients, Nutrient Composition, and Contaminant Levels in NTP-2000 Rat and Mouse Ration...I-1 52
7 Antimony Trioxide, NTP TR APPENDIX J APPENDIX K Sentinel Animal Program...J-1 Analysis of Kras and Egfr Mutations in Wistar Han Rat and B6C3F1/N Mouse Alveolar/bronchiolar Tumors Resulting from Chronic Inhalation Exposure to Antimony Trioxide... K-1 53
8 6 Antimony Trioxide, NTP TR
9 7 ABSTRACT Sb2O3 ANTIMONY TRIOXIDE CAS No Chemical Formula: Sb2O3 Molecular Weight: Synonyms: A1530; A1582; a1588 lp; antimonious oxide; antimony oxide; antimony (III) oxide; antimony peroxide; antimony sesquioxide; antimony white; AP 50; biantimony trioxide; C.I. pigment white 11; dechlorane a-o; diantimony trioxide; exitelite; flowers of antimony; nyacol a 1530; senarmontite; valentinite; weisspiessglanz Trade names: FireShield, Microfine, Montana Brand, Thermoguard, Timonox; TMS, Trutint, Ultrafine, White Star Antimony trioxide (Sb 2O 3) is used as a flame retardant in canvas, textiles, paper, and plastics and in combination with some chlorinated or brominated flame retardants on commercial furniture, draperies, wall coverings, and carpets. It is also used in batteries, enamels and paint pigment, and ceramics and fiberglass. Occupationally, the major sources of exposure to antimony exist in the metal ore smelting and mining industries. Antimony trioxide was nominated by the Consumer Products Safety Commission and The National Institute of Environmental Health Sciences for testing due to the potential for substantial human exposure in occupational settings and the lack of adequate 2-year exposure carcinogenicity studies. Male and female Wistar Han [Crl:WI (Han)] rats and B6C3F1/N mice were exposed to antimony trioxide (greater than 99.9% pure) by inhalation for 2 weeks or 2 years. Genetic toxicology studies were conducted in rat and mouse peripheral blood erythrocytes, peripheral blood leukocytes, and lung cells. 55
10 8 Antimony Trioxide, NTP TR WEEK STUDY IN RATS Groups of five male and five female core study rats were exposed by whole body inhalation to antimony trioxide aerosol at concentrations of 0, 3.75, 7.5, 15, 30, or 60 mg/m 3 for 6 hours plus T 90 (12 minutes) per day, 5 days per week for 12 exposure days during a 16-day period. Additional groups of five female tissue burden study rats were exposed to the same concentrations for 16 days then held for 28 days without exposure. All rats survived to the end of the study. The mean body weights of exposed groups of males and females were similar to those of the respective chamber control groups. Lung weights of 60 mg/m 3 males and 30 and 60 mg/m 3 females were significantly greater than those of the chamber controls. Incidences of chronic active inflammation in the lungs were significantly increased in 30 and 60 mg/m 3 males and females. 2-WEEK STUDY IN MICE Groups of five male and five female core study mice were exposed by whole body inhalation to antimony trioxide aerosol at concentrations of 0, 3.75, 7.5, 15, 30, or 60 mg/m 3 for 6 hours plus T 90 (12 minutes) per day, 5 days per week for 13 exposure days during a 17-day period. Additional groups of five female tissue burden study mice were exposed to the same concentrations for 17 days then held for 28 days without exposure. All mice survived to the end of the study. The mean body weights of exposed groups of males and females were similar to those of the respective chamber control groups. Lung weights were significantly increased in 60 mg/m 3 males and 15 mg/m 3 or greater females. In the larynx, there were significantly increased incidences of squamous metaplasia of the epiglottis in the 30 and 60 mg/m 3 males and females compared to those in the chamber control groups. 2-YEAR STUDY IN RATS Groups of 60 male and 60 female rats were exposed by whole body inhalation to antimony trioxide aerosol at concentrations of 0, 3, 10, or 30 mg/m 3 for 6 hours plus T 90 (12 minutes) per day, 5 days per week for up to 56
11 Antimony Trioxide, NTP TR weeks. Additional groups of 25 tissue burden study female rats were exposed to the same concentrations of antimony trioxide for up to 79 weeks. Survival of 10 and 30 mg/m 3 females was significantly less than that of the chamber control group. The decreased survival in females was attributed primarily to lung proteinosis. In males, the trend towards reduced survival was attributed primarily to lung inflammation and proteinosis. Mean body weights of 30 mg/m 3 males were at least 10% less than those of the chamber control group after week 69 and decreased to 80% of that of the chamber controls by the end of the study. Mean body weights of 3, 10, and 30 mg/m 3 females were at least 10% less than those of the chamber control group after weeks 99, 81, and 65, respectively, and those of 10 and 30 mg/m 3 females were 20% and 28% less, respectively, than that of the chamber control group by the end of the study. Exposure-related clinical findings included abnormal breathing, cyanosis, and thinness in males and females. Lung weights were significantly increased in all exposed groups of males and females at the 12-month interim evaluation. In the lung, there was a positive trend in the incidences of alveolar/bronchiolar adenoma in females in the 2-year study, and the incidences were significantly increased in females exposed to 10 or 30 mg/m 3 ; 30 mg/m 3 females also had one squamous cell carcinoma and two cystic keratinizing epitheliomas. In all exposed groups of males, the incidences of alveolar/bronchiolar adenoma and of alveolar/bronchiolar adenoma or carcinoma (combined) exceeded the historical control ranges for inhalation studies and for all routes of administration. Incidences of chronic active inflammation, alveolar epithelium hyperplasia, proteinosis, and fibrosis in the lung were significantly increased in all exposed groups of males and females at the 12-month interim evaluation and in the 2-year study. Incidences of lymphocytic perivascular cellular infiltration were significantly increased in 3 and 10 mg/m 3 males and females at the 12-month interim evaluation and in 3 and 10 mg/m 3 males and all exposed groups of females in the 2-year study. Incidences of bronchiole epithelium hyperplasia were significantly increased in all exposed groups of males at the 12-month interim evaluation and in all exposed groups of males and females in the 2-year study. The incidences of suppurative alveolar inflammation were significantly increased in all exposed groups of males and females in the 2-year study. The incidence of squamous metaplasia of the alveolar epithelium was significantly increased in 3 mg/m 3 females in the 2-year study. 57
12 10 Antimony Trioxide, NTP TR 590 In the adrenal medulla, the incidences of benign pheochromocytoma were significantly increased in 30 mg/m 3 males and females and the incidence of benign or malignant pheochromocytoma (combined) was significantly increased in 30 mg/m 3 females in the 2-year study. Incidences of adrenal medullary hyperplasia occurred with a positive trend in both males and females in the 2-year study, and the incidences were significantly increased in 30 mg/m 3 males and females. In the 2-year study, incidences of respiratory epithelium hyperplasia in the nose were significantly increased in 3 and 30 mg/m 3 males and 30 mg/m 3 females. The incidences of respiratory epithelium squamous metaplasia in 30 mg/m 3 males and females were significantly increased in the 2-year study. In the 2-year study, the incidence of chronic active inflammation was significantly increased in the larynx of 3 mg/m 3 females. In the bone marrow, incidences of hyperplasia were significantly increased in 30 mg/m 3 males and females in the 2-year study. Incidences of lymphoid hyperplasia in the bronchial and mediastinal lymph nodes were significantly increased in 10 mg/m 3 males and 3 mg/m 3 females at the 12-month interim evaluation and in all exposed groups of males and females in the 2-year study. The incidence of pigmentation was significantly increased in the bronchial lymph nodes of 30 mg/m 3 males in the 2-year study. Chronic active arterial inflammation was observed in multiple tissues in males and females in the 2-year study, including the mediastinum, pancreas, mesentery, lung, and kidney. The combined incidences of chronic active arterial inflammation in all tissues were increased in 10 and 30 mg/m 3 males and females. These increases were significant in 30 mg/m 3 males and 10 and 30 mg/m 3 females. 58
13 Antimony Trioxide, NTP TR In the kidney, the incidences of renal tubule hyaline droplet accumulation were significantly increased in 30 mg/m 3 males and 10 and 30 mg/m 3 females in the 2-year study. The incidence of nephropathy was significantly increased in 30 mg/m 3 females in the 2-year study. Incidences of retinal atrophy were significantly increased in all exposed groups of females in the 2-year study. Incidences of acute inflammation of the ciliary body of the eye were significantly increased in 30 mg/m 3 males and females in the 2-year study. 2-YEAR STUDY IN MICE Groups of 60 male and 60 female mice were exposed by whole body inhalation to antimony trioxide aerosol at concentrations of 0, 3, 10, or 30 mg/m 3 for 6 hours plus T 90 (12 minutes) per day, 5 days per week for up to 105 weeks. Additional groups of 25 tissue burden study female mice were exposed to the same concentrations of antimony trioxide for up to 79 weeks. Survival of 10 and 30 mg/m 3 males and females was significantly less than that of the chamber control groups. Decreases in survival were attributed primarily to alveolar/bronchiolar carcinomas and inflammation of the lung in males and malignant lymphoma and lung inflammation in females. Mean body weights of 30 mg/m 3 males were 10% to 25% less than those of the chamber control group after week 73; mean body weights of 30 mg/m 3 females were at least 10% less than those of the chamber control group after week 85. Exposure-related clinical findings included abnormal breathing and thinness in males and females. Lung weights were significantly increased in all exposed groups of males and in 10 and 30 mg/m 3 females at the 12-month interim evaluation. Thymus weights of 10 and 30 mg/m 3 males and females were significantly increased at the 12-month interim evaluation. Significantly increased incidences of alveolar/bronchiolar carcinoma and alveolar/bronchiolar adenoma or carcinoma (combined) occurred in all exposed groups of males in the 2-year study; these incidences occurred with a positive trend and exceeded the historical control ranges for inhalation studies and for all routes of administration. The incidences of multiple alveolar/bronchiolar carcinoma were also significantly increased in exposed male rats. In female mice, incidences of alveolar/bronchiolar adenoma, alveolar/bronchiolar carcinoma, and 59
14 12 Antimony Trioxide, NTP TR 590 alveolar/bronchiolar adenoma or carcinoma (combined) were significantly increased in all exposed groups in the 2-year study and exceeded the historical control ranges for inhalation studies and for all routes of administration. The incidences of multiple carcinoma were significantly increased in all exposed groups of females. In the lung, incidences of lymphocytic cellular infiltration, chronic active inflammation, pleura fibrosis, pleura inflammation, alveolar epithelium hyperplasia, and bronchiole epithelium hyperplasia were significantly increased in all exposed groups of males and females at the 12-month interim evaluation and in the 2-year study. Incidences of alveolus fibrosis were significantly increased in all exposed groups of males and in 10 and 30 mg/m 3 females at the 12-month interim evaluation; incidences of this lesion were significantly increased in all exposed groups of males and females in the 2-year study. Incidences of malignant lymphoma occurred with a positive trend in females, and were significantly increased in all exposed groups in the 2-year study. In the skin, the incidences of fibrous histiocytoma and fibrous histiocytoma or fibrosarcoma (combined) were significantly increased in 30 mg/m 3 males in the 2-year study. In females, the incidence of squamous cell carcinoma was slightly increased at 30 mg/m 3. In the nose, incidences of chronic active inflammation of the respiratory epithelium were significantly increased in 3 and 10 mg/m 3 males in the 2-year study. The incidence of squamous metaplasia of the respiratory epithelium was significantly increased in 30 mg/m 3 females in the 2-year study. In the larynx, incidences of respiratory epithelium hyperplasia were significantly increased in 10 and 30 mg/m 3 males and 10 mg/m 3 females at the 12-month interim evaluation and in 10 and 30 mg/m 3 males and females in the 2-year study. Incidences of respiratory epithelium squamous metaplasia were significantly increased in 30 mg/m 3 females at the 12-month interim evaluation and in 10 and 30 mg/m 3 males and 30 mg/m 3 females in the 2-year study. Incidences of squamous epithelium hyperplasia were significantly increased in 30 mg/m 3 males and females in the 2-year study. 60
15 Antimony Trioxide, NTP TR In the trachea, the incidence of epithelium hyperplasia was significantly increased in 30 mg/m 3 males in the 2-year study. In the hematopoietic system, incidences of lymphoid hyperplasia in the bronchial lymph nodes were significantly increased in all exposed groups of males and females at the 12-month interim evaluation and in the 2-year study. Incidences of this lesion in the mediastinal lymph node were significantly increased in 30 mg/m 3 males at the 12-month interim evaluation and in 10 and 30 mg/m 3 males and females in the 2-year study. Incidences of this lesion were also significantly increased in the spleen of all exposed groups of females at the 12-month interim evaluation. Also in the hematopoietic system, the incidences of histiocytic cellular infiltration were significantly increased in the bronchial lymph node of 10 mg/m 3 females at the 12-month interim evaluation and 30 mg/m 3 males and 10 and 30 mg/m 3 females in the 2-year study. Incidences of this lesion were also significantly increased in the mediastinal lymph node of 10 and 30 mg/m 3 males and all exposed groups of females in the 2-year study. The incidence of hematopoietic cell proliferation was significantly increased in the spleen of 30 mg/m 3 females in the 2-year study. Incidences of bone marrow hyperplasia were significantly increased in all exposed groups of males and in 10 and 30 mg/m 3 females in the 2-year study. Incidences of cellular depletion were significantly increased in the thymus of 10 and 30 mg/m 3 males and all exposed groups of females in the 2-year study. In the heart, incidences of chronic active inflammation of the epicardium were significantly increased in 10 and 30 mg/m 3 males and females in the 2-year study. The incidence of chronic active inflammation of the forestomach was significantly increased in 30 mg/m 3 males in the 2-year study. GENETIC TOXICOLOGY Antimony trioxide induced small but significant increases in micronucleated erythrocytes in male and female B6C3F1/N mice following exposure for 12 months by inhalation. Significant increases in the percentage of 61
16 14 Antimony Trioxide, NTP TR 590 reticulocytes (immature erythrocytes) were also seen in both male and female mice. In addition, increased levels of DNA damage, assessed using the comet assay, were observed in these same male and female mice in lung tissue samples, but not in peripheral blood leukocytes. No increases in micronucleated red blood cells, percentage of reticulocytes, or DNA damage in lung tissue samples or blood leukocytes were observed in male or female Wistar Han rats following exposure to antimony trioxide for 12 months. TISSUE BURDEN Total antimony trioxide lung burdens and blood antimony concentrations increased with increasing exposure concentration in rats and mice in the 2-week and 2-year studies. Based on the observed deposition of antimony trioxide in the lung, it is presumed that foreign body observed in the lungs of rats and mice in the 2-week studies and the lungs, nose, larynx, trachea, bronchial and mediastinal lymph nodes, and mandibular lymph node (mice only) in the 2-year studies is consistent with the presence of antimony trioxide particles in these tissues. MOLECULAR PATHOLOGY In Wistar Han rats exposed to antimony trioxide by inhalation for 2 years, there was a high incidence of Egfr mutations (13/26) but not Kras mutations (1/26) in alveolar/bronchiolar tumors. The Egfr mutations were localized within exons 18 to 21 and all of them were transitions (G to A or C to T). No Kras or Egfr mutations were noted in the alveolar/bronchiolar tumors that arose spontaneously or in age-matched nontumor lung tissues. Compared to the rats, the mice had higher frequencies of point mutations within hot spot regions of Kras (34/80) in alveolar/bronchiolar tumors. However, the mice also had a relatively high incidence of Kras mutations in the spontaneous alveolar/bronchiolar carcinomas in the chamber controls (3/9), and as a result, the increased incidences of Kras mutations within the exposed groups did not achieve statistical significance. In addition, the majority of Kras mutations in both spontaneous and chemically induced alveolar/bronchiolar tumors were within codon 12 and were G to A transitions. Incidences of Egfr mutations increased with exposure concentration and occurred with a positive trend across the exposure concentration groups. The Egfr mutations were mainly located within exons 18 and 20, and were G to A or C to T transitions. 62
17 Antimony Trioxide, NTP TR CONCLUSIONS Under the conditions of these 2-year inhalation studies, there was some evidence of carcinogenic activity* of antimony trioxide in male Wistar Han rats based on increased combined incidences of alveolar/bronchiolar adenoma or carcinoma in the lung and on increased incidences of benign pheochromocytoma of the adrenal medulla. There was some evidence of carcinogenic activity of antimony trioxide in female Wistar Han rats based on increased incidences of alveolar/bronchiolar adenoma in the lung and on increased combined incidences of benign or malignant pheochromocytoma of the adrenal medulla. The combined occurrence of cystic keratinizing epithelioma and squamous cell carcinoma in the lung may have been related to exposure. There was clear evidence of carcinogenic activity of antimony trioxide in male B6C3F1/N mice based on increased incidences of alveolar/bronchiolar carcinoma of the lung. Increases in the combined incidences of fibrous histiocytoma or fibrosarcoma in the skin of male mice were also considered to be related to exposure. There was clear evidence of carcinogenic activity in female B6C3F1/N mice based on increases in the incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar carcinoma of the lung and on increased incidences of malignant lymphoma. The occurrence of squamous cell carcinoma of the skin may have been related to exposure. Exposure to antimony trioxide resulted in increased incidences of nonneoplastic lesions of the lung, nose, larynx, trachea, bronchial and mediastinal lymph nodes, and bone marrow of male and female rats and mice; the adrenal medulla, arteries of multiple tissues (mesentery, pancreas, mediastinum, kidney, and lung), and eye of male and female rats; the thymus and heart of male and female mice; the forestomach of male mice; and the spleen of female mice. * Explanation of Levels of Evidence of Carcinogenic Activity is on page
18 16 Antimony Trioxide, NTP TR 590 Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Antimony Trioxide Male Wistar Han Rats Female Wistar Han Rats Male B6C3F1/N Mice Female B6C3F1/N Mice Concentrations in air 0, 3, 10, or 30 mg/m 3 0, 3, 10, or 30 mg/m 3 0, 3, 10, or 30 mg/m 3 0, 3, 10, or 30 mg/m 3 Survival rates 30/50, 30/50, 28/50, 18/50 39/50, 38/50, 28/50, 20/50 38/50, 30/50, 27/50, 17/50 36/50, 31/50, 26/50, 15/50 Body weights 30 mg/m 3 group at least 10% less than the chamber control group after week 69 and decreased to 80% of that of the chamber controls by the end of the exposure. 3, 10, and 30 mg/m 3 groups at least 10% less than the chamber control group after weeks 99, 81, and 65, respectively, and were 20% or 28% less than those of the chamber control group in 10 and 30 mg/m 3 by the end of the exposure. 30 mg/m 3 group at least 10% less than the chamber control group after week 73 and 25% less than the chamber control group by the end of the exposure. 30 mg/m 3 group at least 10% less than the chamber control group after week 85 and 21% less than the chamber control group by the end of the exposure. Nonneoplastic effects Lung: foreign body (1/50, 50/50, 50/50, 50/50); inflammation, chronic active (18/50, 50/50, 50/50, 50/50); alveolus, inflammation, suppurative (0/50, 12/50, 24/50, 28/50); perivascular, infiltration cellular, lymphocyte (3/50, 25/50, 19/50, 9/50); proteinosis (0/50, 47/50, 50/50, 50/50); alveolar epithelium, hyperplasia (4/50, 50/50, 48/50, 49/50); bronchiole, epithelium, hyperplasia (3/50, 34/50, 36/50, 33/50); fibrosis (2/50, 50/50, 49/50, 49/50) Adrenal medulla: hyperplasia (1/49, 2/50, 4/49, 8/50) Nose: foreign body (0/50, 0/49, 17/50, 40/50); respiratory (6/50, 15/49, 13/50, 25/50); respiratory epithelium, metaplasia, squamous (0/50, 0/49, 2/50, 6/50) Larynx: foreign body (0/50, 50/50, 50/50, 50/50) Lung: foreign body (0/50, 50/50, 50/50, 50/50); inflammation, chronic active (21/50, 50/50, 50/50, 50/50); alveolus, inflammation, suppurative (0/50, 5/50, 6/50, 5/50); perivascular, infiltration cellular, lymphocyte (0/50, 18/50, 11/50, 8/50); proteinosis (0/50, 50/50, 50/50, 50/50); alveolar (5/50, 50/50, 49/50, 50/50); bronchiole, (6/50, 26/50, 25/50, 27/50); alveolar epithelium, metaplasia, squamous (0/50, 5/50, 3/50, 1/50); fibrosis (1/50, 50/50, 50/50, 49/50) Adrenal medulla: hyperplasia (0/49, 0/49, 3/49, 5/50) Nose: foreign body (0/50, 5/50, 26/50, 45/50); respiratory (4/50, 6/50, 7/50, 16/50); respiratory epithelium, metaplasia, squamous (0/50, 2/50, 3/50, 5/50) Larynx: foreign body (0/50, 50/50, 50/50, 50/50); inflammation, chronic active (0/50, 8/50, 0/50, 3/50) Lung: infiltration cellular, lymphocyte (13/50, 47/50, 48/50, 45/50); foreign body (0/50, 50/50, 50/50, 50/50); inflammation, chronic active (0/50, 48/50, 50/50, 50/50); alveolus, fibrosis (0/50, 12/50, 30/50, 37/50); pluera, fibrosis (0/50, 36/50, 46/50, 50/50); pleura, inflammation (1/50, 40/50, 47/50, 48/50); alveolar (6/50, 39/50, 45/50, 49/50); bronchiole, (0/50, 32/50, 44/50, 44/50) Bone marrow: hyperplasia (10/49, 19/50, 27/48, 33/49) Thymus: depletion cellular (15/41, 14/38, 32/43, 32/39) Nose: foreign body (0/50, 48/49, 48/49, 49/50); respiratory epithelium, active (3/50, 9/49, 9/49, 6/50) Lung: infiltration cellular, lymphocyte (7/50, 37/50, 37/50, 26/50); foreign body (0/50, 50/50, 50/50, 50/50); inflammation, chronic active (1/50, 50/50, 50/50, 50/50); alveolus, fibrosis (0/50, 13/50, 30/50, 38/50); pluera, fibrosis (1/50, 39/50, 50/50, 50/50); pleura, inflammation (4/50, 27/50, 42/50, 38/50); alveolar (1/50, 36/50, 49/50, 48/50); bronchiole, (1/50, 34/50, 48/50, 45/50) Spleen: hematopoietic cell proliferation (17/50, 19/50, 20/50, 35/50) Bone marrow: hyperplasia (3/50, 5/50, 15/50, 28/50) Thymus: depletion cellular (9/47, 18/49, 23/49, 29/49) Nose: foreign body (1/50, 44/49, 45/50, 48/50); respiratory epithelium, metaplasia, squamous (0/50, 3/49, 2/50, 4/50) 64
19 Antimony Trioxide, NTP TR Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Antimony Trioxide Male Wistar Han Rats Female Wistar Han Rats Male B6C3F1/N Mice Female B6C3F1/N Mice Nonneoplastic effects (continued) Trachea: foreign body (0/50, 28/50, 43/50, 48/50) Bone marrow: hyperplasia (0/50, 3/50, 4/50, 8/50) Lymph node, bronchial: foreign body (0/41, 35/40, 45/48, 42/47); hyperplasia, lymphoid (0/41, 21/40, 29/48, 26/47); pigmentation (1/41, 4/40, 5/48, 10/47) Lymph node, mediastinal: foreign body (0/42, 41/45, 41/49, 43/49); hyperplasia, lymphoid (1/42, 24/45, 30/49, 26/49) Mediastinum: artery, active (0/0, 1/1, 2/2, 10/10) Pancreas: artery, active (1/50, 0/50, 2/50, 8/50) Mesentery: artery, active (0/50, 0/50, 0/50, 6/50) Lung: artery, active (0/50, 0/50, 1/50, 1/50) Kidney: renal tubule, accumulation, hyaline droplet (0/50, 1/50, 3/50, 14/50); artery, active (0/50, 0/50, 1/50, 4/50) Trachea: foreign body (0/50, 39/50, 47/50, 49/50) Bone marrow: hyperplasia (8/50, 5/50, 11/50, 20/50) Lymph node, bronchial: foreign body (0/35, 35/36, 23/28, 36/41); hyperplasia, lymphoid (0/35, 21/36, 9/28, 11/41) Lymph node, mediastinal: foreign body (0/46, 27/46, 32/46, 33/46); hyperplasia, lymphoid (0/46, 14/46, 10/46, 15/46) Mediastinum: artery, active (0/0, 0/0, 2/2, 9/9) Pancreas: artery, active (0/50, 0/50, 3/50, 8/50); artery, necrosis (0/50, 0/50, 0/50, 4/50) Mesentery: artery, active (0/50, 0/50, 0/50, 6/50) Lung: artery, active (0/50, 0/50, 1/50, 2/50) Kidney: renal tubule, accumulation, hyaline droplet (0/50, 0/50, 5/50, 11/50); nephropathy (16/50, 15/50, 20/50, 24/50); artery, active (0/50, 0/50, 0/50, 2/50) Larynx: foreign body (0/50, 15/50, 29/50, 44/50); respiratory (1/50, 3/50, 15/50, 30/50); respiratory epithelium, metaplasia, squamous (0/50, 0/50, 8/50, 18/50); squamous (2/50, 0/50, 4/50, 13/50) Trachea: foreign body (0/49, 3/50, 1/50, 20/50); (0/49, 0/50, 2/50, 5/50) Lymph node, bronchial: hyperplasia, lymphoid (2/30, 21/43, 26/47, 13/41); foreign body (0/30, 34/43, 47/47, 38/41); infiltration cellular, histiocyte (0/30, 2/43, 4/47, 6/41) Lymph node, mediastinal: hyperplasia, lymphoid (2/37, 8/45, 17/48, 34/49); foreign body (0/37, 32/45, 42/48, 48/49); infiltration cellular, histiocyte (0/37, 4/45, 13/48, 34/49) Heart: epicardium, active (0/50, 2/50, 7/50, 16/50) Stomach, forestomach: active (2/50, 4/50, 4/49, 7/50) Larynx: foreign body (0/50, 25/50, 39/50, 48/50); respiratory (2/50, 0/50, 14/50, 18/50); respiratory epithelium, metaplasia, squamous (1/50, 0/50, 5/50, 24/50); squamous (4/50, 1/50, 1/50, 12/50) Trachea: foreign body (0/50, 7/50, 14/50, 20/50) Lymph node, bronchial: hyperplasia, lymphoid (2/41, 15/47, 17/48, 11/49); foreign body (0/41, 34/47, 46/48, 43/49); infiltration cellular, histiocyte (0/41, 2/47, 7/48, 7/49) Lymph node, mediastinal: hyperplasia, lymphoid (0/46, 3/48, 16/49, 18/50); foreign body (0/46, 28/48, 45/49, 44/50); infiltration cellular, histiocyte (0/46, 6/48, 11/49, 16/50) Heart: epicardium, active (0/50, 2/50, 7/50, 7/50) Artery (all tissues combined): active (1/50, 1/50, 5/50, 16/50) Artery (all tissues combined): active (0/50, 0/50, 5/50, 15/50) Eye: ciliary body, inflammation, acute (0/49, 0/49, 1/50, 6/49) Eye: retina, atrophy (6/49, 21/50, 18/49, 19/49); ciliary body, inflammation, acute (0/49, 0/50, 1/49, 6/49) 65
20 18 Antimony Trioxide, NTP TR 590 Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Antimony Trioxide Male Wistar Han Rats Female Wistar Han Rats Male B6C3F1/N Mice Female B6C3F1/N Mice Neoplastic effects Lung: alveolar/bronchiolar adenoma (3/50, 4/50, 6/50, 8/50); alveolar/bronchiolar adenoma or carcinoma (3/50, 4/50, 8/50, 8/50) Adrenal medulla: benign pheochromocytoma (1/49, 0/50, 2/49, 7/50) Lung: alveolar/bronchiolar adenoma (0/50, 2/50, 6/50, 5/50) Adrenal medulla: benign pheochromocytoma (0/49, 2/49, 2/49, 6/50); benign or malignant pheochromocytoma (0/49, 2/49, 2/49, 7/50) Lung: alveolar/bronchiolar carcinoma (4/50, 18/50, 20/50, 27/50) Skin: fibrous histiocytoma (0/50, 1/50, 1/50, 4/50); fibrous histiocytoma or fibrosarcoma (0/50, 1/50, 3/50, 4/50) Lung: alveolar/bronchiolar adenoma (1/50, 10/50, 19/50, 8/50); alveolar/bronchiolar carcinoma (2/50, 14/50, 11/50, 11/50); alveolar/bronchiolar adenoma or carcinoma (3/50, 22/50, 27/50, 18/50) All organs: malignant lymphoma (7/50, 17/50, 20/50, 27/50) Equivocal findings None Lung: cystic keratinizing epithelioma or squamous cell carcinoma (0/50, 0/50, 0/50, 3/50) None Skin: squamous cell carcinoma (0/50, 0/50, 0/50, 2/50) Level of evidence of carcinogenic activity Some evidence Some evidence Clear evidence Clear evidence Genetic toxicology Micronucleated erythrocytes Rat peripheral blood in vivo: Mouse peripheral blood in vivo: DNA damage Rat Mouse Negative in males and females Positive in males and females Negative in lung cells and leukocytes (males and females) Positive in lung cells (males and females); negative in leukocytes (males and females) 66
IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS PDE FOR CUMENE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Released for
More informationTOXICOLOGY AND CARCINOGENESIS STUDIES OF GINKGO BILOBA EXTRACT IN F344/N RATS AND B6C3F1/N MICE
NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF GINKGO BILOBA EXTRACT (CAS NO. 90045-36-6) IN F344/N RATS AND B6C3F1/N MICE (GAVAGE STUDIES) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233
More informationNational Toxicology Program
NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES IN Hsd:SPRAGUE DAWLEY SD RATS EXPOSED TO WHOLE-BODY RADIO FREQUENCY RADIATION AT A FREQUENCY (900 MHz) AND MODULATIONS (GSM AND CDMA) USED
More informationTR-469 Toxicology and Carcinogenesis Studies of AZT (CAS No ) and AZT/-Interferon A/D B6C3F1 Mice (Gavage Studies)
(This document has been reformatted unchanged from the original document except for the bold emphasis editing by Stuart Thomson, Director, the Gaia Research Institute. S.T.) TR-469 Toxicology and Carcinogenesis
More informationNeoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture
Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.
More informationSHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
More informationRisk Assessment Approaches for Nanomaterials
Risk Assessment Approaches for Nanomaterials Eileen D. Kuempel, PhD Nanotechnology Research Center Education and Information Division National Institute for Occupational Safety and Health The findings
More informationThe carcinogenicity of benzene. The IARC Monograph Vol 120. Kurt Straif, MD MPH PhD. PSA, Stavanger, 25 October 2018
The carcinogenicity of benzene. The IARC Monograph Vol 120 Kurt Straif, MD MPH PhD PSA, Stavanger, 25 October 2018 The encyclopaedia of The IARC Monographs evaluate Chemicals Complex mixtures Occupational
More informationConflict of Interest Statement
Specific Aspects and Approaches for Regulatory Evaluation of Pharmaceuticals in Two-Year Rodent Carcinogenicity Studies James A. Popp Stratoxon LLC Morgantown, PA Tel: 610.286.7592 popp@stratoxon.com Conflict
More informationDEVELOPMENT OF THE CHROMIUM PUBLIC HEALTH GOAL
DEVELOPMENT OF THE CHROMIUM PUBLIC HEALTH GOAL Robert A. Howd, Ph.D. Chief, Water Toxicology Unit Office of Environmental Health Hazard Assessment, California Environmental Protection Agency Oakland and
More informationAPPENDIX AVAILABLE ON THE HEI WEB SITE
APPENDIX AVAILABLE ON THE HEI WEB SITE Research Report 166 Advanced Collaborative Emissions Study (ACES) Subchronic Exposure Results: Biologic Responses in Rats and Mice and Assessment of Genotoxicity
More informationHuman health effects of antimony an update
Human health effects of antimony an update Dr. R.V. Battersby EBRC Consulting GmbH Karine Van de Velde i2a Secretary General Raffaelstr. 4 30177 Hannover Germany Public perception of HH effects of antimony
More informationAddendum to the 12th Report on Carcinogens
Addendum to the 12th Report on Carcinogens Published by the U.S. Department of Health and Human Services, National Toxicology Program The twelfth edition of the National Toxicology Program (NTP) Report
More informationof 3-Aminophenol in B6D2F1 Mice
Summary of Drinking Water Carcinogenicity Study of 3-Aminophenol in B6D2F1 Mice July 2012 Japan Bioassay Research Center Japan Industrial Safety and Health Association PREFACE The tests were contracted
More informationPHARMACOLOGY AND TOXICOLOGY MANAGEMENT OF CDER CARCINOGENICITY ASSESSMENT COMMITTEE (CAC) AND EXECUTIVE CAC CONTENTS
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 7412.1 PHARMACOLOGY AND TOXICOLOGY MANAGEMENT OF CDER CARCINOGENICITY ASSESSMENT COMMITTEE (CAC) AND EXECUTIVE CAC CONTENTS
More informationSpontaneous Neoplasms and Survival in Wistar Han Rats: Compilation of Control Group Data. March, 2003
Spontaneous Neoplasms and Survival in Wistar Han Rats: Compilation of Control Group Data March, 2003 Information Prepared by Mary L.A. Giknis Ph.D Charles B. Clifford D.V.M, Ph.D TABLE OF CONTENTS INTRODUCTION...1
More informationAPR RE: Docket Numbers 94P-0420 and FDA-2008-P /CP. Dear Dr. Epstein:
DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration College Park, MD 20740 APR 1-2014 SamuelS. Epstein, M.D. Cancer Prevention Coalition University of Illinois at
More information4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms
212 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Deposition, retention, clearance and metabolism The absorption and distribution of indium is highly dependent on its
More informationEpithelial tumors. Dr. F.F. Khuzin, PhD Dr. M.O. Mavlikeev
Epithelial tumors Dr. F.F. Khuzin, PhD Dr. M.O. Mavlikeev Epithelial tumors Tumors from the epithelium are the most frequent among tumors. There are 2 group features of these tumors: The presence in most
More informationCOMMITTEE ON CARCINOGENICITY OF CHEMICALS IN FOOD, CONSUMER PRODUCTS AND THE ENVIRONMENT
COMMITTEE ON CARCINOGENICITY OF CHEMICALS IN FOOD, CONSUMER PRODUCTS AND THE ENVIRONMENT STATEMENT ON A CARCINOGENICITY STUDY OF ASPARTAME BY THE EUROPEAN RAMAZZINI FOUNDATION COC/06/S2 December 2006 Introduction
More informationSummary of Feed Carcinogenicity Study. of Diphenylamine. in F344 Rats
Summary of Feed Carcinogenicity Study of Diphenylamine in F344 Rats August 2011 Japan Bioassay Research Center Japan Industrial Safety and Health Association PREFACE The tests were contracted and supported
More informationSpontaneous Neoplastic Lesions in the CrI:CD-1(ICR) Mouse in Control Groups from 18 Month to 2 year Studies. March, 2005
Spontaneous Neoplastic Lesions in the CrI:CD-1(ICR) Mouse in Control Groups from 18 Month to 2 year Studies March, 2005 Information Prepared by Mary L.A. Giknis Ph.D Charles B. Clifford D.V.M, Ph.D 1063
More informationFigure 2: Lymph node Cortical follicular (F) and paracortical (PC) atrophy, with narrowing of the cortex relative to the medulla (M).
Figure 1: Lymph node Follicular hyperplasia, with expansion of the follicular germinal centres (F) by large blast cells. Paracortical hyperplasia, with expansion of the paracortex (PC) by small lymphocytes.
More informationGlyphosate Cancer Risks and Failures of the Pesticide Regulatory Process
Glyphosate Cancer Risks and Failures of the Pesticide Regulatory Process Christopher J. Portier, Ph.D. 11 October, 2017 Brussels, Belgium Disclosures The opinions expressed here and the analyses done to
More informationSummary of Inhalation Carcinogenicity Study. of Tetrachloroethylene. in BDF 1 Mice
Summary of Inhalation Carcinogenicity Study of Tetrachloroethylene in BDF 1 Mice March 1993 Japan Bioassay Laboratory Japan Industrial Safety and Health Association PREFACE The tests were contracted and
More informationSpontaneous Neoplastic Lesions in the Crl:CD-1 (ICR)BR Mouse. March, 2000
Spontaneous Neoplastic Lesions in the Crl:CD-1 (ICR)BR Mouse March, 2000 Information Prepared by Mary L. A. Giknis, Ph.D. Charles B. Clifford, D.V.M., Ph.D. CHARLES RIVER LABORATORIES TABLE OF CONTENTS
More informationOPINION of the French Agency for Environmental and Occupational Health Safety
The Director General Maisons-Alfort, France, 15 June 2009 OPINION of the French Agency for Environmental and Occupational Health Safety Relating to establishing carcinogenic HTVs by inhalation for carbon
More informationFDA Expectations and Evaluation of Inhalation Toxicology Studies
FDA Expectations and Evaluation of Inhalation Toxicology Studies Presented by Timothy McGovern, Ph.D. SciLucent, LLC Herndon, Virginia Development of inhalation products has unique regulatory aspects My
More informationDavid B. Warheit Ph.D, Chemours Company, Wilmington, Delaware USA
How Does One Interpret the Relevance of Particle Overload/ Rat Lung Tumor Findings in Chronic Inhalation Studies with PSPs for Assessing Human Occupational Health Risks? David B. Warheit Ph.D, Chemours
More informationgallium arsenide EC number: CAS number:
Committee for Risk Assessment RAC Annex 1 Background document to the Opinion proposing harmonised classification and labelling at Community level of gallium arsenide ECHA/RAC/CLH-0000000792-73-03/A1 gallium
More informationSummary of Inhalation Carcinogenicity Study. of Isopropyl Acetate. in F344 Rats
Summary of Inhalation Carcinogenicity Study of Isopropyl Acetate in F344 Rats March 2009 Japan Bioassay Research Center Japan Industrial Safety and Health Association PREFACE The tests were contracted
More information7/12/2012. Respiratory system. Respiratory Response to Toxic Injury (Lung) Ninth Industrial Toxicology and Pathology Short Course.
Ninth Industrial Toxicology and Pathology Short Course 23 27 July, 2012 Contemporary Concepts in Target Organ Toxicologic Pathology Respiratory system Respiratory Response to Toxic Injury (Lung) Eric Wheeldon
More informationSCOPE OF PRACTICE PGY-5
Recognize normal cytomorphology of cells derived from the respiratory, gastrointestinal, and genitourinary tracts, and body fluid (Cerebrospinal fluid, pleural and peritoneal fluid) Recognize normal cytomorphology
More informationThe decision on actual implementation depends on the results of a further consequence analysis.
00- allylamine interim TSD Probit function technical support document Date: February 0 Document id: 00-allylamine-interim Status: interim Author: drs. W. ter Burg, RIVM substance name CAS number Allylamine
More informationAFIP MINIBOARD EXAMINATION MAY 2008 LAB ANIMAL PATHOLOGY
AFIP MINIBOARD EXAMINATION MAY 2008 LAB ANIMAL PATHOLOGY 1. Hallmark lesions of infection with polytropic strains of mouse hepatitis virus include: A. Lymphocytic syncytia in mesenteric lymph nodes B.
More informationCASE REPORTS. Inflammatory Polyp of the Bronchus. V. K. Saini, M.S., and P. L. Wahi, M.D.
CASE REPORTS V. K. Saini, M.S., and P. L. Wahi, M.D. I n 1932 Jackson and Jackson [l] first reported a number of clinical cases under the title Benign Tumors of the Trachea and Bronchi with Especial Reference
More informationMaria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1
Maria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1 1 National Institute of Health Dr. Ricardo Jorge 2 General-Directorate of Health, Lisbon, Portugal Venice.,10-03-2015 The number
More informationOrgans of the Respiratory System Laboratory Exercise 52
Organs of the Respiratory System Laboratory Exercise 52 Background The organs of the respiratory system include the nose, nasal cavity, sinuses, pharynx, larynx, trachea, bronchial tree, and lungs. They
More informationChallenges in Nonclinical Development of Inhalation Drug Products
Challenges in Nonclinical Development of Inhalation Drug Products Luqi Pei, Ph.D. Senior Pharmacologist DPARP, CDER August 6, 2015 Rockville, MD Disclaimer This speech reflects the views of the speaker
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationGeography of Pulmo Park: Landmarks. Cards 1A
Geography of Pulmo Park: Landmarks Cards 1A Directions: Cut out the cards, fold and laminate and then hand out to students (one each). If you have more cards than students, some students will have more
More information(which was not peer-reviewed) is the author/funder, who has granted biorxiv a license to display the preprint in perpetuity.
Report of Partial Findings from the National Toxicology Program Carcinogenesis Studies of Cell Phone Radiofrequency Radiation in Hsd: Sprague Dawley SD rats (Whole Body Exposures) Draft 5-19-2016 Table
More informationINTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE Q3D(R1)
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GUIDELINE FOR ELEMENTAL IMPURITIES (R1) Draft version Endorsed on 18 May 2018
More informationMultifunctional acrylate toxicology - Results of new studies generated for REACH
Multifunctional acrylate toxicology - Results of new studies generated for REACH RadTech UV&EB Conference May 2, 2012 Maureen Waite, MS Manager, Toxicology and Product Stewardship Cytec Coating Resins
More informationEvaluation of Potential Carcinogenicity
Toxicology for Industrial and Regulatory Scientists Evaluation of Potential Carcinogenicity i i James A. Popp D.V.M., Ph.D. Stratoxon LLC Lancaster, PA April 29, 2015 Lecture Outline History of carcinogenicity
More information2014 SEVPAC Case #63 (Slide ID: #1)
2014 SEVPAC Case #63 (Slide ID: #1) Tuskegee University College of Veterinary Medicine Dr. Ebony Gilbreath Tissues submitted to TUSVM diagnostic services for histopathology Puppies 4 weeks of age From
More informationInterim Specific Ground Water Criterion o, m, p-cresol. Alan H. Stern, Dr.P.H., D.A.B.T. Office of Science NJDEP 2/25/10
Interim Specific Ground Water Criterion o, m, p-cresol Alan H. Stern, Dr.P.H., D.A.B.T. Office of Science NJDEP 2/25/10 Introduction Scope of this Assessment The purpose of this assessment is to derive
More informationGAF Safety Data Sheet SDS # 2027 SDS Date: December 2014
GAF Safety Data Sheet SDS # 2027 SDS Date: December 2014 SECTION 1: PRODUCT AND COMPANY INFORMATION PRODUCT NAME: TRADE NAME: CHEMICAL NAME / SYNONYM: CHEMICAL FAMILY: MANUFACTURER: EVERGUARD FIBERGLASS
More informationSubject: Assessing the Potential Risk of Human Exposure to Tetrachloroethylene (Perchloroethylene) and Formaldehyde
Memo Date: June 20, 2006 To: From: Shelly Burman, Minnesota Pollution Control Agency Hillary Carpenter, Health Risk Assessment Unit Subject: Assessing the Potential Risk of Human Exposure to Tetrachloroethylene
More informationORIGIN OF PULMONARY TUMORS IN RATS INDUCED BY 4-NITROQUINOLINE 1-OXIDE. (Plates I-V)
[GANN, 57, 1-7; February, 1966] UDC 616-006-021.6[616.24]:547.831.6-31:616.24-006-031.6 ORIGIN OF PULMONARY TUMORS IN RATS INDUCED BY 4-NITROQUINOLINE 1-OXIDE (Plates I-V) Kazuo MORI, Jo HIRATSUKA, Shuhei
More information5. Summary of Data Reported and Evaluation
FORMALDEHYDE 273 5. Summary of Data Reported and Evaluation 5.1 Exposure data Formaldehyde is produced worldwide on a large scale by catalytic, vapour-phase oxidation of methanol. Annual world production
More informationA Weight of Evidence Approach to Cancer Assessment. Alan R Boobis Imperial College London
A Weight of Evidence Approach to Cancer Assessment Alan R Boobis Imperial College London a.boobis@imperial.ac.uk Disclosure Statement Member of Board of Trustees of ILSI, Board of Directors of ILSI Europe
More informationToxStrategies, Inc. and Summit Toxicology
Deborah Proctor Chad Thompson, Mark Harris, Mina Suh, Laurie Haws, Chris Kirman and Sean Hays ToxStrategies, Inc. and Summit Toxicology November 2012 Research Project funded by the Cr 6 Panel of the American
More informationEvaluation of Ramazzini Institute Aspartame Studies and EFSA s Assessment
Evaluation of Ramazzini Institute Aspartame Studies and EFSA s Assessment Lisa Y. Lefferts, MSPH Senior Scientist Center for Science in the Public Interest Who is CSPI and What is Our Agenda? CSPI is a
More informationHISTOLOGY. Simple squamal lungs
HISTOLOGY Lab Objectives: Students should be able to... 1. Visually identify each class of tissue and examples within each class 2. Indicate the location (in the human body and/or organ) and function of
More informationPartial Results of NTP Chronic Carcinogenicity Studies of Cell Phone Radiofrequency Radiation in Rats
Partial Results of NTP Chronic Carcinogenicity Studies of Cell Phone Radiofrequency Radiation in Rats Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. Director National Institute of Environmental Health Sciences
More informationThe respiratory system structure and function
Name: Class: Date: Active reading 11A + Biology Gr11A The respiratory system structure and function The function of the respiratory system is to bring oxygen into the body and eliminate carbon dioxide
More informationTo: Recipients of JACC 42. HV/mls/JACC 42 corrigendum Brussels, 15 December 2004
EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS AISBL To: Recipients of JACC 42 HV/mls/JACC 42 corrigendum Brussels, 15 December 2004 Dear Sir or Madam, Corrigenda to JACC No. 42 - Tetrafluoroethylene
More informationA Probabilistic Approach for the Assessment of Internal Dose to Chronic Lymphocytic Leukemia Precursor Cells
A Probabilistic Approach for the Assessment of Internal Dose to Chronic Lymphocytic Leukemia Precursor Cells James W. Neton 1 A. Iulian Apostoaei 2 B. John R. Trabalka 2 1 U.S. National Institute for Occupational
More informationScience, Hazard and Risk in the European Union: The Case of TiO 2 Exposures
Science, Hazard and Risk in the European Union: The Case of TiO 2 Exposures David B. Warheit Ph.D, Chemours Company, Wilmington, Delaware USA Inhaled Particles XII Meeting, Glasgow, UK September 25, 2017
More informationHuman Body Systems Study Guide
Human Body Systems Study Guide Nervous System 1. Brain stem part of nervous system and controls the heartbeat and breathing by controlling the cardiac muscle and diaphragm. Also receives information from
More informationKnockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling
SUPPLEMENTARY INFORMATION Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling Jian-Guo Ren 1, Pankaj Seth 1, Clary B. Clish 2, Pawel K. Lorkiewicz
More informationDate Printed: 16/NOV/2004 Date Updated: 12/MAR/2004 Version 1.2 According to 91/155/EEC
SIGMA-ALDRICH Material Safety Data Sheet Date Printed: 16/NOV/2004 Date Updated: 12/MAR/2004 Version 1.2 According to 91/155/EEC Classified as Hazardous according to the criteria of EU Annex 1 and NOHSC.
More informationAnatomy and Physiology 1 Chapter 4 Outline Tissues and Membranes
Anatomy and Physiology 1 Chapter 4 Outline Tissues and Membranes 1 Tissue group of cells with similar structure and function o 4 major groups epithelial, connective, muscle, nerve Epithelial tissue (Fig
More informationTable of Contents. Preface xi. Acknowledgments xiii. Part I Overview of the Diagnostic Process 1. 1 Overview of Grading and Staging 3
Table of Contents Preface xi Acknowledgments xiii Part I Overview of the Diagnostic Process 1 1 Overview of Grading and Staging 3 Identification of the process 3 Identification of tumor types 5 Grading
More informationThe stability of historical control data for common neoplasms in laboratory rats and the implications for carcinogenic risk assessment
Regulatory Toxicology and Pharmacology xxx (2004) xxx xxx Regulatory Toxicology and Pharmacology www.elsevier.com/locate/yrtph The stability of historical control data for common neoplasms in laboratory
More informationEnvironmental Exposures and Cancer Hazards
Environmental Exposures and Cancer Hazards Ruth Lunn, DrPH Director, Office of the Report on Carcinogens Division of the National Toxicology Program National Institute of Environmental Health Sciences
More informationThe Lymphoid System Pearson Education, Inc.
23 The Lymphoid System Introduction The lymphoid system consists of: Lymph Lymphatic vessels Lymphoid organs An Overview of the Lymphoid System Lymph consists of: Interstitial fluid Lymphocytes Macrophages
More informationCommittee for Risk Assessment RAC. Opinion proposing harmonised classification and labelling at EU level of. Titanium dioxide
Committee for Risk Assessment RAC Opinion proposing harmonised classification and labelling at EU level of Titanium dioxide EC Number: 236-675-5 CAS Number: 13463-67-7 CLH-O-0000001412-86-163/F Adopted
More informationEthylene Oxide
Ethylene Oxide 75-21-8 Hazard Summary The major use of ethylene oxide is as a chemical intermediate in the manufacture of ethylene glycol. Ethylene oxide is also used as a sterilizing agent for medical
More informationRespiratory Pathology. Kristine Krafts, M.D.
Respiratory Pathology Kristine Krafts, M.D. Normal lung: alveolar spaces Respiratory Pathology Outline Acute respiratory distress syndrome Obstructive lung diseases Restrictive lung diseases Vascular
More informationNOT CLASSIFIED AS HAZARDOUS ACCORDING TO CRITERIA OF WORKSAFE AUSTRALIA
SAFETY DATA SHEET MATILDA LITE PLY (LIGHTWEIGHT PLYWOOD) WOOD VENEER PRODUCT NOT CLASSIFIED AS HAZARDOUS ACCORDING TO CRITERIA OF WORKSAFE AUSTRALIA IMPORTANT NOTICE: This Safety Data Sheet (SDS) is written
More information5.15 HEXYTHIAZOX (176)
Hexythiazox 225 5.15 HEXYTHIAZOX (176) TOXICOLOGY Hexythiazox is the ISO approved name for (trans-5-(4-chlorophenyl)-n-cyclohexyl-4-methyl-2-oxo- 3-thiazolidine-carboxamide (CAS No. 78587-05-0). Hexythiazox
More informationCarcinogenicity of Diesel Exhaust: Old and New Technology Diesel
April 5-7, 2016 Carcinogenicity of Diesel Exhaust: Old and New Technology Diesel Katherine Walker Senior Scientist Health Effects Institute Boston, MA Who is the Health Effects Institute? An independent,
More informationObjectives. Objectives 9/11/2012. Chapter 7 Body Systems. Define term connective tissue. Identify five body cavities
Chapter 7 Body Systems Objectives Define term connective tissue Identify five body cavities Define terms joints, cartilage, ligaments, tendons Identify two major divisions of skeletal system and describe
More informationDiagnostic Cytology of Cancer Cases
Diagnostic Cytology of Cancer Cases Somporn Techangamsuwan Companion Animal Cancer Research Unit (CAC-RU) Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University 1 Tumor or Non-tumor
More informationSpontaneous Neoplastic Lesions in Aged Sprague-Dawley Rats
Exp. Anim. 50(2), 99 103, 2001 Spontaneous Neoplastic Lesions in Aged Sprague-Dawley Rats Motokuni NAKAZAWA, Takeharu TAWARATANI, Hiroshi UCHIMOTO, Akitaka KAWAMINAMI, Makoto UEDA, Akiko UEDA, Yasuhiko
More informationTHE RESPIRATORY SYSTEM
THE RESPIRATORY SYSTEM Functions of the Respiratory System Provides extensive gas exchange surface area between air and circulating blood Moves air to and from exchange surfaces of lungs Protects respiratory
More informationDate Printed: 03/03/2004 Date Updated: 09/02/2002 Version 1.4. Product Name ANTIMONY(III) OXIDE, POWDER, <5 MICRON,99% Product Number
SIGMA-ALDRICH MATERIAL SAFETY DATA SHEET Date Printed: 03/03/2004 Date Updated: 09/02/2002 Version 1.4 Section 1 - Product and Company Information Product Name ANTIMONY(III) OXIDE, POWDER,
More informationLymphoid System: cells of the immune system. Answer Sheet
Lymphoid System: cells of the immune system Answer Sheet Q1 Which areas of the lymph node have most CD3 staining? A1 Most CD3 staining is present in the paracortex (T cell areas). This is towards the outside
More informationHazard Data: Low concentrations of crystalline silica (SiO2) in the form of quartz, cristobalite or tridymite may be present.
SECTION 1 IDENTIFICATION Product Trade Name................................................... Generic Description......................................................Mixture Manufacturer/Supplier.........................................Procor
More informationRecommendations for Aerosol Applications of Silicone-Based Materials
Recommendations for Aerosol Applications of Silicone-Based Materials September 2001 Revised March 2018 This document provides information and recommendations relevant to formulating aerosol products containing
More informationLYMPHATIC ANATOMY LAB. BIO 139 ANATOMY AND PHYSIOLOGY II MARY CATHERINE FLATH, Ph.D.
LYMPHATIC ANATOMY LAB BIO 139 ANATOMY AND PHYSIOLOGY II MARY CATHERINE FLATH, Ph.D. THE LYMPHATIC SYSTEM ORGANS PRIMARY BONE MARROW THYMUS SECONDARY LYMPH NODES SPLEEN FUNCTIONS CONTROL DISEASE TRANSPORT
More informationSection 5.3: Preclinical safety data
Section 5.3: Preclinical safety data SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationWhat is lung cancer? Contents
13 11 20 Information and support What is lung cancer? Contents About the lungs What is lung cancer? How common is it? Different types of lung cancer Causes Symptoms Information reviewed by About the lungs
More informationLamitex GPO3 SAFETY DATA SHEET. Section 1: Chemical Property and Company Identification
Franklin Fibre-Lamitex Corporation 903 East 13 th Street, Wilmington, DE 19802 USA Phone: 302.652.3621 Toll Free: 800.233.9739 Fax : 302.571.9754 Email: info@franklinfibre.com Web: www.franklinfibre.com
More informationCancer Risk Factors in Ontario. Other Radiation
Cancer Risk Factors in Ontario Other Radiation OTHer radiation risk factor/ exposure Radon-222 and decay products X-radiation, gamma radiation Cancer The context where high risks were reported Magnitude
More information6 th Reprint Handbook Pages AJCC 7 th Edition
6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint
More informationSupplementary Figure 1. Genotyping strategies for Mcm3 +/+, Mcm3 +/Lox and Mcm3 +/- mice and luciferase activity in Mcm3 +/Lox mice. A.
Supplementary Figure 1. Genotyping strategies for Mcm3 +/+, Mcm3 +/Lox and Mcm3 +/- mice and luciferase activity in Mcm3 +/Lox mice. A. Upper part, three-primer PCR strategy at the Mcm3 locus yielding
More informationCLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
More informationMaterial Safety Data Sheet. Antimony Trioxide TMS /Timonox Red Star/Fireshield H/Thermoguard S
SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product name: Product Use Description: Flame Retardant Company: Chemtura Corporation 199 Benson Road Middlebury, CT 06749 United States of America Telephone:
More informationNorcross, GA TRANSPORTATION EMERGENCIES (24 Hrs.): CHEMTREC (800) GENERAL INFORMATION : (770)
SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION Issue Date: 5-4-05 Trade Name: Developer Systems Cleaner Kit ( Parts A, B and Neutralizer) Chemical Name: Mixtures- Parts A, B, & Neutralizer Synonyms: None
More informationID NO. EPA-HQ-ORD
Methanol Institute Comments on the U.S. EPA Draft Toxicological Review of Methanol (IRIS) Docket ID NO. EPA-HQ-ORD-2009-0398 March 15, 2010 Mr. John Lynn President and CEO 4100 N. Fairfax Drive Suntec
More informationTasks of BAuA. Toxicity and Risk of DCM and alternative solvents in paint strippers. baua_vorlagen.ppt
Toxicity and Risk of DCM and alternative solvents in paint strippers Tasks of BAuA Support the ministry of labour (BMA) Implementation and transfer of knowledge Research Dr. B. Orthen Toxicology of hazardous
More informationThe MSDS format adheres to the standards and regulatory requirements of the United States and may not meet regulatory requirements in other countries.
The MSDS format adheres to the standards and regulatory requirements of the United States and may not meet regulatory requirements in other countries. DuPont Page 1 "Krytox" TM7 10716PP Revised 3-AUG-2001
More informationIntegrated Risk Information System
Page 1 of 8 Integrated Risk Information System Recent Additions Contact Us Search: EPA Home > Browse EPA Topics > Human Health > Health Effects > IRIS Home > IRIS Summaries 1,4-Dioxane (CASRN 123-91-1)
More informationA. Incorrect! The alveolus is where gas exchange takes place. B. Correct! Surfactant is the lipid-rich material that permits lung inflation.
Toxicology - Problem Drill 13: Respiratory Toxicology No. 1 of 10 1. The lipid-rich material that decreases surface tension of the alveoli, allowing sacs to inflate properly and remain inflated during
More informationSESSION 1: GENERAL (BASIC) PATHOLOGY CONCEPTS Thursday, October 16, :30am - 11:30am FACULTY COPY
SESSION 1: GENERAL (BASIC) PATHOLOGY CONCEPTS Thursday, October 16, 2008 9:30am - 11:30am FACULTY COPY GOAL: Describe the basic morphologic (structural) changes which occur in various pathologic conditions.
More informationNTP Toxicology and Carcinogenicity Studies of Cell Phone Radiofrequency Radiation
NTP Toxicology and Carcinogenicity Studies of Cell Phone Radiofrequency Radiation Michael Wyde, PhD, DABT National Toxicology Program National Institute of Environmental Health Sciences June 8, 2016 BioEM2016
More informationVICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing
6 November 2014 EMA/CVMP/VICH/526/2000 Committee for Medicinal Products for Veterinary Use (CVMP) VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing
More information